Drug Trial Radar · NCT06988670
A Phase 2 Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism
Last checked: Nov 19, 2026Latest source record: May 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
35
Planned (sponsor's estimate)
Start
May 5, 2025
Primary completion
May 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Extend Biosciences Inc.Industry
- Sponsor type
- Industry
- First posted
- May 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to investigate the safety, tolerability and efficacy of EXT608 in adults with hypoparathyroidism.
Conditions
- Hypoparathyroidism
Interventions
EXT608Drug
Modified version of parathyroid hormone attached to vitamin D to extend half-life
PlaceboOther
Placebo for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess the safety and tolerability of multiple subcutaneous (SC) escalating dose levels of EXT608 in participants with hypoparathyroidism by determining frequency and severity of treatment emergent adverse events and post-dose change in lab resultsTime frame: From enrollment until the end of treatment at 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Trial Site
Buenos Aires, Buenos Aires F.D., Argentina · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.